Comparison of Tetropium and β2 Agonist Therapy in Patients with Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis

Dehghan , Hamidreza; Yazdani Shormasti , Neda; Rezaei , Nima

Volume 25, Issue 6 (Aug 2017) JSSU 2017, 25(6): 485-500 | Back to browse issues page

Mendeley

Zotero

RefWorks

Dehghan H, Yazdani Shormasti N, Rezaei N. Comparison of Tetropium and β2 Agonist Therapy in Patients with Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis . JSSU 2017; 25 (6) :485-500
URL: http://jssu.ssu.ac.ir/article-1-3881-en.html

Comparison of Tetropium and β2 Agonist Therapy in Patients with Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis

Hamidreza Dehghan

, Neda Yazdani Shormasti ^*

, Nima Rezaei

Abstract: (4900 Views)

Introduction: The long-acting anticholinergic Tiotropium, which used in the treatment of patients with chronic obstructive pulmonary disease, prescribed once a day, unlike other bronchodilators that used several times a day for patients. The study was a systematic review that examined the effectiveness and safety of β2 Agonists and Tiotropium in the patients with chronic obstructive pulmonary disease.
Methods: RCT(randomized controlled trials) and CCT (controlled clinical trials) studies that compared Tiotropium and β2 agonists extracted from PubMed, SCOPUS, Ovid Medline and Cochran databases regardless of the time limitation were studied. Only studies were reviewed that were in English. In total, eight articles have been evaluated. Meta-analysis was performed using STATA software
Conclusions: The results showed less efficacy based on two outcomes include FEV1(Forced expiratory volume in 1 second) and FEV1 / FVC, and a little higher efficacy based on other outcomes such as (FVC). In terms of safety it can be said, the overall incidence of adverse events in both treatments was the same and it has been reported from moderate to severe according to the findings. Mostly, serious side effects were in form of intensifying attacks. The percentage of patients with severe complications in the Tiotropium group were less than Salmeterol group (0.9 vs. 3.1%, p = 0.04). In addition, a limited number of deaths observed in both treatment which were often unrelated to the applied treatment.
Conclusion: The results showed that Tiotropium treatment compared to β2 agonists was superior to safety. On the other hand, it showed less efficacy in the efficacy outcomes (FEV1 and FEV1 / FVC), and in the case of (FVC) effectiveness at a higher rate.

Keywords: Tiotropium, Anticholinergics, Bronchodilators, β2 agonists, Chronic Obstructive Pulmonary Disease, Efficacy, Safety

Full-Text [PDF 990 kb] (1274 Downloads)

Type of Study: Original article | Subject: General
Received: 2016/09/10 | Accepted: 2016/11/26 | Published: 2017/11/1

References

1. Osthoff M, Jenkins C, Leuppi JD. Chronic obstructive pulmonary disease–a treatable disease. Swiss medical weekly 2013;143:1-8.

2. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American j respiratory and critical care medicine 2013; 187(4): 347-65.

3. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respiratory research 2013; 14: 49.

4. Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory J 2004; 23(6): 932-46.

5. Anto J, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. European Respiratory J 2001; 17(5): 982-94.

6. Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema. An eight-year study of early chronic obstructive lung disease in working men in London: Oxford University Press, 37 Dover Street, London. W1X 4AH; 1976.

7. Gold DR, Wang X, Wypij D, Speizer FE, Ware JH, Dockery DW. Effects of cigarette smoking on lung function in adolescent boys and girls. New England J Med 1996; 335(13): 931-7.

8. Venkat Narayan KM, Ali MK, Koplan JP. Global noncommunicable diseases—where worlds meet. New England J Med 2010; 363: 1196-98.

9. Vlahos R, Bozinovski S. Preclinical murine models of Chronic Obstructive Pulmonary Disease. European j pharmacology 2015; 759: 265-71.

10. Diaz-Guzman E, Mannino DM. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clinics in chest medicine 2014; 35(1): 7-16.

11. Jaganath D, Miranda JJ, Gilman RH, Wise RA, Diette GB, Miele CH, et al. Prevalence of chronic obstructive pulmonary disease and variation in risk factors across four geographically diverse resource-limited settings in Peru. Respiratory res 2015; 16(1): 40.

12. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance---United States, 1971--2000. Respiratory care 2002; 47(10):1184-99.

13. Prakash A, Babu KS, Morjaria JB. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. International J chronic obstructive pulmonary disease 2015; 10: 111-123.

14. van Dijk WD, van den Bemt L, Van Weel C. Megatrials for bronchodilators in chronic obstructive pulmonary disease (COPD) treatment: time to reflect. The J the American Board of Family Medicine 2013; 26(2): 221-4.

15. Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cheyne, Leanne Cochrane Database of Systematic Rev 2015; 9(9).

16. Liesker JJ, Wijkstra PJ, Ten Hacken NH, Koëter GH, Postma DS, Kerstjens HA. A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. CHEST J 2002; 121(2): 597-608.

17. Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respiratory res 2010; 11(1): 135.

18. Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respiratory medicine 2014; 108(12): 1752-60. [Persion]

19. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. European Respiratory J 2011; 38(4): 797-803.

20. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. The Cochrane database of systematic rev 2012; 9: CD009157.

21. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New England J Med 2008; 359(15): 1543-54.

22. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England J Med 2007; 356(8): 775-89.

23. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New England J Med 2011; 364(12): 1093-103.

24. Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, Di Marco F, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respiratory medicine 2004; 98(12): 1214-21.

25. Briggs DD, Jr., Doherty DE. Long-term pharmacologic management of patients with chronic obstructive pulmonary disease. Clinical cornerstone 2004; 6(2): 17-28.

26. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2006; 58(5): 399-404.

27. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. CHEST J 2002; 122(1): 47-55.

28. Spencer S, Karner C, Cates Christopher J, Evans David J. Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2011; (12). Available from: http://onlinelibrary.wiley.com/ doi/ 10.1002/ 14651858. CD007033. pub3/ abstract.

29. Briggs D, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulmonary pharmacology & therapeutics 2005; 18(6): 397-404.

30. Donohue JF. Therapeutic responses in asthma and COPD. Bronchodilators. Chest. 2004 Aug;126(2 Suppl):125S-37S; discussion 59S-61S. PubMed PMID: 15302773. Epub 2004. eng.